NovMetaPharma Co Ltd
229500
Company Profile
Business description
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company also sells C01 and CZ raw materials to partners conducting joint research and development, and also sells health functional foods.
Contact
727 Eonju-ro
13th floor, Nonhyeon-dong, Trees Building
Gangnam-gu
Seoul
KORT: +82 25381893
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
20
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,727.37 | 73.12 | 0.96% |
| DAX 40 | 23,667.32 | 179.99 | 0.77% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,164.75 | 48.06 | 0.53% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |